In January 2014, 4D Molecular Therapeutics signed a broad collaboration and license agreement with uniQure (QURE, NASDAQ), a leader in human gene therapy. Under this agreement, uniQure gained access to 4D’s AAV vector discovery and optimization technology, Directed Vector Evolution TM, for gene delivery to treat diseases within the central nervous system and liver.
uniQure is delivering on the promise of gene therapy, single treatments with potentially curative results. uniQure has developed a modular platform to rapidly bring new disease modifying therapies to patients with severe disorders. Their approach is validated by multiple partnerships and the regulatory approval of their lead product Glybera.